CLINUVEL PHARMACEUTICALS LTD Annual General Meeting - Notice of Meeting & Explanatory Memorandum 2022
CLINUVEL released the formal Notice of Meeting and Explanatory Memorandum for its...
Read More
CLINUVEL confirms AGM date
CLINUVEL confirms the date for the Company’s 2022 Annual General Meeting.
Read More
CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients
European regulatory submission follows clinical support for SCENESSE® treatment in EPP patients...
Read More
CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2022
CLINUVEL PHARMACEUTICALS LTD hosted an investor webinar on the financial results for...
Read More
Revenue Growth Drives CLINUVEL's Sixth Consecutive Annual Profit
CLINUVEL today announced its sixth consecutive annual net profit, driven by revenues...
Read More
Dividend/Distribution – CUV
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report
Read More
Appendix 4E & Annual Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 23 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Notice of ceasing to be a substantial holder
Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Notice of change of interests of initial substantial holder
Melbourne, Australia, 25 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Notice of initial substantial holder
Melbourne, Australia, 20 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 12 May 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More